Spots Global Cancer Trial Database for Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Official Title: A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Study ID: NCT04109482
Study Description
Brief Summary: A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN
Detailed Description: The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102. The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope Medical Center, Duarte, California, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Duke University, Durham, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Lihua E Budde, MD
Affiliation: City of Hope Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
